Abstract
INTERLEUKIN-2 is an autocrine growth factor for T cells1,2 which also activates other cells including B cells3 and natural killer cells4. The subunits of the interleukin-2 receptor (IL-2R) lack intrinsic enzymatic activity, but protein tyrosine phosphorylation is a critical event following ligand binding and src family kinases, such as Lck, are known to be activated by IL-2 (refs 5–9). However, IL- 2 signalling can occur in the absence of receptor interaction with Lck, suggesting that other protein tyrosine kinases might be important10. Here we report that a new member of the Janus family of kinases (Jak-3) is coupled to the IL-2R in human peripheral blood T cells and natural killer cells.
This is a preview of subscription content
Access options
Subscribe to Journal
Get full journal access for 1 year
204,58 €
only 4,01 € per issue
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.
References
Taniguchi, T. & Minami, Y. Cell 73, 5–8 (1993).
Waldman, T. A. A. Rev. Biochem. 58, 875–911 (1989).
Waldman, T. A. et al. J. exp. Med. 160, 1450–1466 (1984).
Henry, C. S., Kwibayashi, K., Kern, D. E. & Gillis, S. Nature 291, 335–338 (1981).
Minami, Y., Kono, T., Miyazaki, T. & Taniguchi, T. A. Rev. Immun. 11, 245–267 (1993).
Mills, G. B. et al. J. biol. Chem. 265, 3561–3567 (1990).
Farrar, W. L. & Ferris, D. K. J. biol. chem. 264, 12562–12567 (1989).
Merida, I. & Gaulton, G. N. J. biol. Chem. 265, 5690–5694 (1990).
Hatakeyama, M. et al. Science 262, 1523–1528 (1991).
Hatakeyama, M., Mori, H., Doi, T. & Tanaguchi, T. Cell 59, 837–845 (1989).
Kawamura, M. et al. Proc. natn. Acad. Sci. U.S.A. (in the press).
Watling, D. et al. Nature 366, 166–170 (1993).
Velasquez, L., Fellows, M., Stark, G. R. & Pellegrini, S. Cell 70, 313–322 (1992).
Muller, M. et al. Nature 366, 129–135 (1993).
Taniguchi, T. A. Rev. Immun. 4, 69–96 (1988).
Leonard, W. J., Depper, J. M., Robb, R. J., Waldmann, T. A. & Greene, W. C. Proc. natn. Acad. Sci. U.S.A. 80, 6957–6961 (1983).
Stahl, N. et al. Science 263, 92–95 (1994).
Kirken, R. A., Rui, H., Evan, G. A. & Farrar, W. L. J. biol. Chem. 268, 22765–22770 (1993).
Argetsinger, L. S. et al. Cell 74, 237–244 (1993).
Silvennoinen, O., Ihle, J. N., Schlessinger, J. & Levy, O. E. Nature 366, 583–585 (1993).
Silvennoinen, O. et al. Proc. natn. Acad. Sci. U.S.A. 90, 8429–33 (1993).
Witthuhn, B. A. et al. Cell 74, 227–236 (1993).
Russell, S. M. et al. Science 262, 1880–1887 (1993).
Kondo, M. et al. Science 262, 1874–1877 (1993).
Kishimoto, T., Taga, T. & Akira, S. Cell 76, 253–262 (1994).
Stahl, N. & Yancopoulos, G. D. Cell 74, 587–590 (1993).
Pellegrini, S. & Schridler, C. Trends biochem. Sci. 18, 338–342 (1993).
Witthuhn, B. A. et al. Nature 370, 153–157 (1994).
Author information
Affiliations
Rights and permissions
About this article
Cite this article
Johnston, J., Kawamura, M., Kirken, R. et al. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature 370, 151–153 (1994). https://doi.org/10.1038/370151a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/370151a0
Further reading
-
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach
Nature Reviews Rheumatology (2022)
-
Endothelial Jak3 expression enhances pro-hematopoietic angiocrine function in mice
Communications Biology (2021)
-
JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
Nature Reviews Gastroenterology & Hepatology (2020)
-
Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders
Current Hematologic Malignancy Reports (2019)
-
Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma
Leukemia (2018)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
